These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24897816)

  • 1. Cardiovascular prevention: lifestyle and statins--competitors or companions?
    Opie LH; Dalby AJ
    S Afr Med J; 2014 Mar; 104(3):168-73. PubMed ID: 24897816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Present status of statin therapy.
    Opie LH
    Trends Cardiovasc Med; 2015 Apr; 25(3):216-25. PubMed ID: 25802224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
    Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
    J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidemia: management using optimal lipid-lowering therapy.
    Ito MK
    Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention.
    Chapman MJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):135-9. PubMed ID: 16025232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan　- A Retrospective Database Analysis.
    Umeda T; Hayashi A; Harada A; Okuyama K; Baxter CA; Tokita S; Teramoto T
    Circ J; 2018 May; 82(6):1605-1613. PubMed ID: 29628458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins and the cholesterol mortality paradox.
    Nunes JP
    Scott Med J; 2017 Feb; 62(1):19-23. PubMed ID: 27889702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of diet and lifestyle modifications in the statin era.
    Hu FB
    J Am Diet Assoc; 2005 Nov; 105(11):1718-21. PubMed ID: 16256755
    [No Abstract]   [Full Text] [Related]  

  • 19. Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia.
    Bosomworth NJ
    J Am Board Fam Med; 2016 Nov; 29(6):727-740. PubMed ID: 28076256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.